Canada’s AbCellera Biologics and US-based company Pfizer have collaborated, whereby the former will discover function-modulating antibodies against undisclosed membrane protein targets using its monoclonal antibody (mAb) screening platform.

The new multi-year, therapeutic antibody discovery collaboration is aimed at generating lead antibody candidates against membrane targets with the help of the mAb discovery platform.

AbCellera founding CEO Carl Hansen said: “Our platform allows us to screen natural immune repertoires with unparalleled depth to unlock the most challenging discovery programmes.

“This partnership reinforces our commitment to offer leading-edge antibody discovery capabilities and to create value for companies by providing access to our platform. We welcome the opportunity to work closely with the innovative team at Pfizer and look forward to building a lasting relationship.”

Under the agreement, the company will receive an upfront payment, as well as research support.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

It will also be eligible to receive approximately $90m in contingent milestone payments.

"We are pleased to work with the team at AbCellera using their innovative antibody discovery platform."

Based on Pfizer’s development and commercialisation of antibodies that may be generated under this collaboration, AbCellera will be eligible for tiered mid-to-low single digit royalty payments.

Pfizer Biomedicines Design vice-president Will Somers said: “We are pleased to work with the team at AbCellera using their innovative antibody discovery platform.

“We hope this platform can aid in our research as we look to bring novel medicines to patients, seeking to discover modulators of a transmembrane protein in a therapeutically important target class.”

AbCellera’s single cell antibody discovery platform provides the ability to pharmaceutical and biotechnology partners to identify mAb therapeutic candidates from the natural immune repertoires of any species.

Image: The entrance to Pfizer World Headquarters in Manhattan, New York, US. Photo: courtesy of Coolcaesar.